Emerging medical therapies for congenital adrenal hyperplasia
[version 1; peer review: 4 approved]

Phyllis W. Speiser
Pediatrics, Zucker School of Medicine at Hofstra-Northwell Health, Lake Success, New York, 11042-2062, USA

Abstract
Congenital adrenal hyperplasia has traditionally been treated with daily oral doses of glucocorticoids and mineralocorticoid supplements. Such therapy does not precisely replicate the adrenal cortex's circadian pattern. As a consequence, patients are intermittently overtreated or undertreated leading to growth suppression in children, excess weight gain and altered metabolism. Several new treatments are on the horizon. This article will summarize some new potential therapies as adjuncts to, or replacement for, standard therapy.

Keywords
congenital adrenal hyperplasia, treatment

Corresponding author: Phyllis W. Speiser (pspeiser@northwell.edu)

Author roles: Speiser PW: Conceptualization, Data Curation, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: The author has served as a medical consultant to Neurocrine Biosciences, San Diego, CA and has been considered for participation in several planned clinical trials.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Speiser PW. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Speiser PW. Emerging medical therapies for congenital adrenal hyperplasia [version 1; peer review: 4 approved] F1000Research 2019, 8(F1000 Faculty Rev):363 (https://doi.org/10.12688/f1000research.17778.1)

First published: 02 Apr 2019, 8(F1000 Faculty Rev):363 (https://doi.org/10.12688/f1000research.17778.1)
Introduction

Congenital adrenal hyperplasia (CAH) is caused by one of several inherited enzyme deficiencies. The most common form of the classic disorder, found in about 1:14,000 to 1:18,000 births, is steroid 21-hydroxylase deficiency. Mutations in CYP21A2 (P450c21) impair adrenocortical production of cortisol and frequently aldosterone and lead to the accumulation of adrenal sex steroids\(^1\). Allelic variation accounts for most phenotypic differences. Cardinal features of classic CAH include atypical development of the external genitalia in girls with manifest virilization. Both males and females have salt wasting with failure to thrive and potentially fatal hypovolemia and shock. Newborn screening, now universal in the US\(^6\) and in many developed countries\(^1\), can mitigate these complications (reviewed in 4). Despite life-saving glucocorticoid (GC) and mineralocorticoid (MC) oral therapies, treatment does not precisely replicate adrenal physiology. Individuals with CAH commonly experience adverse outcomes in terms of growth, metabolic, reproductive, and mental health endpoints\(^1-4\). This discussion of emerging medical treatments will be restricted to the classic or severe forms of steroid 21-hydroxylase deficiency.

Improved glucocorticoid delivery

Normal adrenocortical secretion has a circadian rhythm quite distinct from that of blood cortisol levels achieved by administering two or three daily oral doses of GC medication\(^1,5\). Hydrocortisone (HC) subcutaneous delivery for 6 months via a programmed pump in eight adults with classic CAH produced significant reduction in adrenal androgens with improvement in quality of life and fatigue\(^6\). Though conceptually attractive and perhaps applicable to highly motivated patients who are inadequately managed by conventional treatment, pump management is complex. An early trial with a once-daily modified-release oral HC preparation (Chronocort, Diurnal, Cardiff, UK) given to 16 adults with classic CAH decreased adrenal androgen precursors despite a slightly reduced daily HC dose\(^6\). However, subsequent phase 3 trials apparently failed to demonstrate superiority to standard HC treatment and this potential new treatment is currently on hold. A different type of modified-release GC (Plendadrin, Shire, London, UK) is approved in Europe for adrenal insufficiency but has not been formally tested in CAH.

In the US, the lowest-dose HC tablet is 5 mg, and in Europe 10 mg, excessive for infants and young children. Availability of pediatric-dose formulations would eliminate concerns about improper compounding of HC from tablets\(^1,11,12\). Based on favorable trial results\(^11\), the European Medicines Agency has approved very-low-dose HC 1 mg granules (Alkindi, Diurnal) for treatment of adrenal insufficiency or CAH in infants and children. A US Food and Drug Administration new drug application is said to be pending.

Androgen/estrogen antagonists and synthesis inhibitors

To ameliorate the effects of adrenal androgen excess, females with CAH often need treatment additional to GC replacement. Such treatments may include dermatologic therapies for acne and hirsutism or additional hormone treatments (or both) to regulate menses or aid conception. All steroidogenic pathways to androgens and estrogens depend on activity of the enzyme 17-hydroxylase/17,20-lyase (P450c17, CYP17A1). Abiraterone acetate is an orally active, potent P450c17 inhibitor\(^16\) indicated for treatment of castration-resistant prostate cancer\(^15,16\). Short-term adjunctive treatment with 250 mg/day abiraterone acetate (alongside standard steroid replacement) normalized the predose serum androstenedione levels in all six women with poorly controlled classic CAH\(^16\). Because abiraterone acetate also inhibits gonadal steroid production and could be teratogenic, its use in CAH would be limited to pre-pubertal children, women using contraceptives, or men who receive gonadal replacement. A clinical trial is under way in pre-pubertal children with CAH (ClinicalTrials.gov Identifier: NCT02574910) with the goal of minimizing exogenous GC and endogenous adrenal sex steroid hormone exposure in order to normalize growth and pubertal development.

Growth-promoting drugs

A systematic review and meta-analysis of adult height in individuals with classic CAH diagnosed before the age of 5 years included just over 1000 children in 35 studies that met the eligibility criteria\(^14\). The pooled data indicated a corrected adult height standard deviation (SD) of −1.0. The average heights were 169 cm (66.5 inches) for men and 157 cm (61.8 inches) for women, both within the normal range for shorter than average adults in the general population. These data obviate the routine use of growth-promoting medications that are considered only for individuals whose heights were expected to be at least −2.25 SDs. Subgroup analysis revealed that the addition of early MC treatment was associated with increased height outcome\(^14\).

A 2001 report tested growth hormone alone (n = 12) or in combination with leuprolide acetate (n = 8) to enhance growth in CAH patients with evidence of early puberty. Follow-up over 2 years showed improved predicted adult height, but as of this date, no data have been published to document actual adult heights\(^19\). A proof-of-concept trial demonstrated that co-administration of growth hormone plus an aromatase inhibitor (again, alongside standard steroid replacement) improved adult height in a single adolescent male patient with CAH\(^20\).

Since normal adult height may be achieved through judicious use of standard GC and MC therapies, further long-term prospective randomized and carefully controlled studies are needed to determine whether the use of growth-promoting drugs is safe and cost-effective in individuals with CAH. At present, such treatments are not considered standard care in children with CAH.

Other medical strategies

Reducing adrenocorticotropic hormone (ACTH) production is another mechanism for minimizing adrenal androgen excess. In a small trial of eight women with classic CAH, the selective corticotropin-releasing hormone receptor type 1 antagonist, NBI-77860, was added to conventional therapy\(^21\), resulting in a more than 40% reduction in the morning ACTH surge and about 27% lower serum 17OHP. Variable reductions of androstenedione and testosterone were observed.
Mitrane, a different type of adrenolytic used for treatment of adrenocortical cancer and Cushing syndrome, was administered to a man with classic CAH and testicular adrenal rest tumors (TARTs) who was infertile for 2 years. Adrenal androgen precursors were suppressed and TARTs regressed. Paternity was achieved following an increase in sperm count. Mitrane is a potential teratogen (pregnancy category D) and induces CYP3A4, increasing GC clearance, and therefore is not considered a useful adjunct to CAH therapy. ATR-101 (ClinicalTrials.gov Identifier: NCT02804178), which inhibits acyl co-A cholesterol acyltransferase and shares some mechanisms cause the development of gonadal adrenal rest tumors that secrete androgens. For these reasons, the initial enthusiasm has been tempered by long-term complications. Individuals who are known to be non-adoherent are poor candidates for adrenalectomy. A systematic review of bilateral adrenalectomy in CAH identified 48 cases ranging from infancy to adulthood and most were carried out for uncontrolled androgen excess or iatrogenic Cushing syndrome (or both) caused by administration of large GC doses to achieve control. Post-operative amelioration of these symptoms was noted in most patients, including three women who were able to conceive following adrenalectomy. In contrast, 40% of patients experienced adverse outcomes, including eight patients with adrenal crisis and one death in an infant. Five males developed adrenal rest tumors requiring surgical removal. Unexpectedly, two males had regression of TARTs. The conclusion from this review is that adrenalectomy is effective for relief of refractory adrenal androgen excess, but that candidates for adrenalectomy must be chosen judiciously and educated extensively regarding post-operative risks.

**Adrenalectomy**

Adrenalectomy reduces virilization in females and permits decreased GC doses but this is considered a rather radical approach because of surgical risk. Moreover, there is an increased risk of life-threatening adrenal crisis with absolute dependence on exogenous hormone replacement and loss of potentially beneficial hormones—for example, dehydroepiandrosterone (DHEA) and epinephrine—from the adrenal medulla. A final consideration is that adrenalectomy may inadvertently cause the development of gonadal adrenal rest tumors that secrete androgens. For these reasons, the initial enthusiasm has been tempered by long-term complications. Individuals who are known to be non-adoherent are poor candidates for adrenalectomy. A systematic review of bilateral adrenalectomy in CAH identified 48 cases ranging from infancy to adulthood and most were carried out for uncontrolled androgen excess or iatrogenic Cushing syndrome (or both) caused by administration of large GC doses to achieve control. Post-operative amelioration of these symptoms was noted in most patients, including three women who were able to conceive following adrenalectomy. In contrast, 40% of patients experienced adverse outcomes, including eight patients with adrenal crisis and one death in an infant. Five males developed adrenal rest tumors requiring surgical removal. Unexpectedly, two males had regression of TARTs. The conclusion from this review is that adrenalectomy is effective for relief of refractory adrenal androgen excess, but that candidates for adrenalectomy must be chosen judiciously and educated extensively regarding post-operative risks.

**Epinephrine deficiency**

Individuals with classic CAH have adrenomedullary insufficiency because GCs are required for development and regulation of the adrenal medulla. The physiologic responses of glucose, insulin, and leptin pathways are dysregulated during exercise among adolescent patients lacking both cortisol and epinephrine. The clinical implications of epinephrine deficiency are not fully known, but it may contribute to hypoglycemia during febrile illnesses, especially in young children, and impair the response to stress. Decreased epinephrine production has been observed in newborns with classic CAH compared with controls; norepinephrine levels were similar. Epinephrine replacement or supplementation has not been studied. It is not known whether a compensatory norepinephrine response is sufficient.

**Gene therapy**

In two decades since the initial report that adenoviral gene therapy transiently restored enzyme activity in a mouse model of 21-hydroxylase deficiency, there have been no human trials. Animal research is ongoing, and intravenous injection of an adenoviral-Cyp21a1 vector in such mice allowed functional enzyme expression in adrenal tissue, resulting in weight gain, near normal progesterone levels, and improved stress response for more than 15 weeks. However, in another laboratory setting, the therapeutic effect lasted only 8 weeks. Auto-transplantation of Cyp21a1-expressing fibroblasts into 21-hydroxylase–deficient mouse subcutaneous tissue or direct injection of adenovirus-Cyp21a1 constructs into mouse muscle demonstrated enzyme efficacy for about 4 weeks. Thus, both adrenal and extra-adrenal induction of Cyp21a1 can temporarily ameliorate steroid metabolism in 21-hydroxylase null mice. It is unclear whether the murine data will be translated into effective human treatments. Permanent correction of mutations causing CAH with gene therapy directed at a patient’s own adrenal stem cells would theoretically cure CAH and supplant imperfect steroid replacement. Cell-based therapies and gene-editing technology now in development may be options for disease cure in the future.

**Grant information**

The author declared that no grants were involved in supporting this work.

**References**

1. Krone N, Dhir V, Ivison HE, et al.: Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. *Clin Endocrinol (Oxf)*. 2007; 66(2): 162–72. Published Abstract | Publisher Full Text
2. National Newborn Screening and Global Resource Center: National Newborn Screening System. In: Center NNSGR, ed. Newborn Screening Reports and Publications. National Newborn Screening & Global Resource Center; 2006; 2017.
3. Gidtöf S, Wedell A, Guthenberg C, et al.: Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden: a 25-year longitudinal prospective population-based study. *JAMA Pediatr*. 2014; 168(6): 567–74. Published Abstract | Publisher Full Text
4. Speiser PW, Arit W, Auchtus RU, et al.: Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018; 103(11): 4043–88. Published Abstract | Publisher Full Text
5. Arit W, Willis DS, Wild SH, et al.: Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. *J Clin Endocrinol Metab*. 2010; 95(11): 5110–21. Published Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation
6. Finkelstein GP, Kim MS, Sinaii N, et al.: Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2012; 97(12): 4429–38. Published Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation
7. Debono M, Ghobadi C, Rostami-Hodjegan A, et al.: Modified-release
hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):1548–54. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

8. Weitzman ED, Fukushima D, Nogeire C, et al.: Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab. 1971;33(1):14–22. PubMed Abstract | Publisher Full Text

9. Nella AA, Mallappa A, Perritt AF, et al.: A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2016;101(12):4690–8. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

10. Mallappa A, Saini N, Kumar P, et al.: A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2015;100(3):1137–45. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

11. Barillas JE, Eichner D, van Wagoner R, et al.: Larotrectinib Cushing Syndrome in a Child With Congenital Adrenal Hyperplasia: Erroneous Compounding of Hydrocortisone. J Clin Endocrinol Metab. 2018;103(1):7–11. PubMed Abstract | Publisher Full Text

12. Neumann U, Burusdi S, Spielmann S, et al.: Quality of compounded hydrocortisone capsules used in the treatment of children. Eur J Endocrinol. 2017;177(2):229–34. PubMed Abstract | Publisher Full Text | F1000 Recommendation

13. Neumann U, Whitaker MJ, Wiegand S, et al.: Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clin Endocrinol (Oxf). 2018;88(1):21–9. PubMed Abstract | Publisher Full Text | F1000 Recommendation

14. Garrido M, Peng HM, Yoshimoto FK, et al.: A-ring modified steroidal azoles retaining similar pot and slowly reversible CYP17A1 inhibition as abiraterone. J Steroid Biochem Mol Biol. 2014;143:1–10. PubMed Abstract | Publisher Full Text | Free Full Text

15. de Bono JS, Logothetis CJ, Molina A, et al.: Abiraterone acetate to lower prostate-specific antigen levels and achieve clinical benefit in men with metastatic castration-resistant prostate cancer: an open-label, randomized phase 3 trial. J Clin Oncol. 2012;30(2):1453–60. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

16. Ryan CJ, Molina A, Grifin T, Abiraterone in Metastatic Prostate Cancer. N Engl J Med. 2013;368(15):1458–69. PubMed Abstract | Publisher Full Text

17. Auchtus RJ, Buschor EO, Chang HY, et al.: Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99(8):2763–70. PubMed Abstract | Publisher Full Text | Free Full Text

18. Muthusamy K, Elamir MB, Smushkin G, et al.: Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95(9):4161–72. PubMed Abstract | Publisher Full Text | F1000 Recommendation

19. Quintos JB, Vogiatzis MG, Harbison MD, et al.: Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2001;86(4):1511–7. PubMed Abstract | Publisher Full Text

20. Hawton K, Walton-Betancourt S, Rumsby G, et al.: Growth Hormone With Aromatase Inhibitor May Improve Height in CYP11B1 Congenital Adrenal Hyperplasia. Pediatrics. 2017;139(2):e20160730. PubMed Abstract | Publisher Full Text | F1000 Recommendation

21. Tercero AF, Spencer-Segal JL, Father RH, et al.: Single-Dose Study of a Corticosterone-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2016;101(3):1174–80. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation

22. Begu-Gauliard H, Cartes A, Young J: Mitotane for 21-hydroxylase deficiency in an infertile man. N Engl J Med. 2014;371(2):2042–4. PubMed Abstract | Publisher Full Text

23. Cheng Y, Kerpola RE, Kerpola TK: ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo. Endocr Relat Cancer. 2016;23(4):1–19. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Referee Status: ✔️ ✔️ ✔️ ✔️ ✔️

Version 1

Referee Report 02 April 2019
https://doi.org/10.5256/f1000research.19438.r46296

Peter C Hindmarsh
Institute of Child Health, University College London, London, UK

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 02 April 2019
https://doi.org/10.5256/f1000research.19438.r46295

Maria G Vogiatzi
Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 02 April 2019
https://doi.org/10.5256/f1000research.19438.r46297

Roberto Salvatori
Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Anna Nordenström
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.